Table 1

Presentation and final outcome of cases with recalcitrant fungal keratitis that received intrastromal voriconazole

NoDay of presentationInitial BCVASize of infiltrateSize of epithelial defectOrganism isolatedInterventionFU (days)Final BCVA
14520/12006.0×7.23.0×4.4AspergillusINJ=13520/200
244FCCF6.4×6.83.2×4.2AspergillusINJ=24220/200
330PL+7.4×7.84.0×6.2FusariumINJ=3, PK5020/40
428FCCF5.4×6.23.2×4.6AspergillusINJ=23620/200
544HMCF5.8×6.43.8×4.8FusariumINJ=13320/120
636HMCF6.0×7.24.2×4.4AspergillusINJ=23220/300
738FCCF6.8×7.44.8×6.4CulvulariaINJ=23820/300
840PL+5.4×7.83.2×6.2FusariumINJ=24620/200
932PL+5.2×7.43.8×5.4AspergillusINJ=24420/300
105420/12005.4×7.24.4×6.2AspergillusINJ=33420/200
1146FCCF6.2×8.25.4×6.8AspergillusINJ=3, PK5520/40
1214PL+4.0×5.43.2×4.2AspergillusINJ=23220/120
  • BCVA, best-corrected visual acuity; F, female; FCCF, finger counting close to face; FU, follow-up; HMCF, hand movement close to face; INJ, number of intrastromal voriconazole injection; M, male; PK, therapeutic penetrating keratoplasty; PL+, light perception present.